



- (51) **International Patent Classification:**  
*C12N 9/10* (2006.01) *C12N 9/22* (2006.01)
- (21) **International Application Number:**  
PCT/US2024/021853
- (22) **International Filing Date:**  
28 March 2024 (28.03.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
63/492,978 29 March 2023 (29.03.2023) US  
63/505,888 02 June 2023 (02.06.2023) US
- (71) **Applicant: SCRIBE THERAPEUTICS INC.** [US/US];  
1150 Marina Village Parkway, Alameda, California 94501 (US).
- (72) **Inventors; and**
- (71) **Applicants: FERNANDES, Jason** [US/US]; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **CHARLES, Emeric Jean Marius** [FR/US]; c/o Scribe Therapeutics Inc., 1150 Marina Village

Parkway, Alameda, California 94501 (US). **WRIGHT, Addison** [US/US]; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **HIGGINS, Sean** [US/US]; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **DENNY, Sarah** [US/US]; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **DEMAREE, Benjamin** [US/US]; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **WHITE, Ross** [US/US]; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **OAKES, Benjamin** [US/US]; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **DEITER, Fred** [US/US]; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US).

- (74) **Agent: ROY, Madhuri** et al.; Cooley LLP, 1299 Pennsylvania Ave., NW, Suite 700, Washington, District of Columbia 20004 (US).

- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

- (54) **Title:** COMPOSITIONS AND METHODS FOR THE TARGETING OF PCSK9

LTRP # + ADD


**N and C terminal fusions**



**C terminal fusions**



**N terminal fusions**



**FIG. 1**

- (57) **Abstract:** Provided herein are gene repressor systems comprising fusion proteins, such as fusion proteins comprising catalytically-dead Class 2, Type V CRISPR proteins, and guide nucleic acids (gRNA) useful in the repression of a proprotein convertase subtilisin/kexin Type 9 (*PCSK9*) gene. Also provided are methods of making, and methods of using such systems to repress transcription of *PCSK9*.

[Continued on next page]

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,  
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,  
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))